Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SHR-4849 injection plus other antitumor agents in malignant solid tumors
CTR20252306Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4849 in Non-hematologic malignancy, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2025; status: active.
02
Drugs
SHR-4849
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20252306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252306.